84 results about "Farnesyl pyrophosphate" patented technology

Disclosed are methods for suppressing the induction of inducible nitric oxide synthase in a cell comprising contacting said cell with an effective amount of at least one induction suppressor of inducible nitric oxide synthase or a cytokine are disclosed. The induction suppressor can be an inhibitor of mevalonate synthesis, an inhibitor of the farnesylation of Ras, an antioxidant, an enhancer of intracellular cAMP, an enhancer of protein kinase A (PKA), an inhibitor of NF-kβ activation, an inhibitor of Ras/Raf/MAP kinase pathway, an inhibitor of mevalonate pyrophosphate decarboxylase or an inhibitor of farnesyl pyrophosphate.

The invention features methods for producing isoprene from cultured cells having increased expression levels and/or activity levels of a mevalonate kinase polypeptide and an isoprene synthase polypeptide. The invention also provides methods for producing isoprene from cultured cells having reduced accumulation of intermediates (such as mevalonate, isopentenyl diphosphate, 3,3-dimethylallyl diphosphate, geranyl diphosphate, or farnesyl diphosphate) in the biosynthesis of isoprene or isoprenoids that may otherwise cause undesirable amounts of growth inhibition, toxicity, or cell death. The resulting isoprene compositions may have increased yields and/or purity of isoprene.

The present invention is directed to variant squalene synthase enzymes, including Saccharomyces cerevisiae squalene synthase enzymes, and to nucleic acid molecules encoding these variant enzymes. These variant enzymes produce squalene at a lower rate than the wild-type enzyme, allowing more farnesyl pyrophosphate to be utilized for production of isoprenoid compounds, while still producing sufficient squalene to allow the S. cerevisiae cells to grow without the requirement for supplementation by sterols such as ergosterol. These variant enzymes, therefore, are highly suitable for the efficient production of isoprenoids.

The present invention is directed to variant squalene synthase enzymes, including Saccharomyces cerevisiae squalene synthase enzymes, and to nucleic acid molecules encoding these variant enzymes. These variant enzymes produce squalene at a lower rate than the wild-type enzyme, allowing more farnesyl pyrophosphate to be utilized for production of isoprenoid compounds, while still producing sufficient squalene to allow the S. cerevisiae cells to grow without the requirement for supplementation by sterols such as ergosterol. These variant enzymes, therefore, are highly suitable for the efficient production of isoprenoids.

A unique carotenogenic biosynthetic gene cluster has been isolated from Panteoa agglomerans strain DC404, wherein the genetic organization of the cluster is crtE-idi-crtY-crtI-crtB-crtZ. The genes contained within this cluster encode geranylgeranyl pyrophosphate (GGPP) synthetase (CrtE), isopentenyl pyrophosphate isomerase (Idi), lycopene cyclase (CrtY), phytoene desaturase (CrtI), phytoene synthase (CrtB), and β-carotene hydroxylase (CrtZ). The gene cluster, genes and their products are useful for the conversion of farnesyl pyrophosphate to carotenoids. Vectors containing those DNA segments, host cells containing the vectors and methods for producing those enzymes by recombinant DNA technology in transformed host organisms are disclosed.

The invention discloses a farnesyl pyrophosphate synthase gene as well as a coded protease and application thereof. The gene is obtained by clone from salviamiltiorrhizabge by utilizing a cDNA chip technology, which fills the blank of separating and cloning the farnesyl pyrophosphate synthase gene from a rare traditional Chinese medicine of salviamiltiorrhizabge. The farnesyl pyrophosphate synthase gene has a nucleotide sequence shown as SEQ ID NO.1, or a homological sequence adding, substituting, inserting or lacking one or more nucleotides or allelic genes and derived nucleotide sequence thereof. The protein coded by the gene has an amino acid sequence shown as SEQ ID NO.2 or a homological sequence adding, substituting, inserting or lacking one or more amino acids. The farnesyl pyrophosphate synthase gene can improve the content of tanshinone which is diterpene active element in the salviamiltiorrhizabge by the biotechnology, is beneficial to the quality improvement of the salviamiltiorrhizabge medicine, can be used for the breeding selection and has good application prospect.

The invention relates to sesquiterpene synthases from Patchouli plants (Pogostemon cablin), and methods of their production and use. In one embodiment, the invention provides nucleic acids comprising a nucleotide sequence as described herein that encodes for at least one sesquiterpene synthase. In a further embodiment, the invention also provides for sesquiterpene synthases and methods of making and using these enzymes. For example, sesquiterpene synthases of the invention may be used to convert farnesyl-pyrophosphate to various sesquiterpenes including patchoulol, γ-curcumene and other germacrane-type sesquiterpenes.

Genes have been isolated from strain DC260, a member of the Enterobacteriaceae family, encoding geranylgeranyl pyrophosphate (GGPP) synthetase (CrtE), phytoene synthase (CrtB), phytoene desaturase (CrtI), lycopene cyclase (CrtY), β-carotene hydroxylase (CrtZ), and zeaxanthin glucosyl transferase (CrtX) activity. The genes and their products are useful for the conversion of farnesyl pyrophosphate to carotenoids. Vectors containing those DNA segments, host cells containing the vectors and methods for producing those enzymes by recombinant DNA technology in transformed host organisms are disclosed.

The invention discloses a method for constructing a high-yield sclareol engineering strain by a synthetic biology methdo, and an application thereof. The construction method for the strain relates to express plant sourced key enzymes for synthesizing sclareol, wherein the key enzymes comprise a pyrophosphoric acid ladanum enediol ester synthase and a sclareol synthase; and overexpress a combination of one or more yeast endogenous enzyme-based genes, wherein the enzyme-based genes comprise a key enzyme of a mevalonic acid approach-(hydroxymethyl) coenzyme A reductase, and two enzymes of an isopentenylpyrophosphate approach-a farnesyl pyrophosphate synthase and a geranylgeranyl diphosphate synthase. The method can efficiently produce sclareol, with a shake flask fermentation level reaches 9 mg/l, and has industrial application prospects.

The invention discloses a terpenoid synthase for producing nerolidol and application thereof, and belongs to the field of synthetic biology. Terpene synthase TPF09930 for producing the nerolidol is provided, a nucleotide sequence of the terpene synthase TPF09930 is as shown in SEQIDNO:2, the terpene synthase TPF09930 is combined with mevalonic acid pathway related genes to construct a strain for producing the nerolidol. By overexpression of Escherichia coli XL1 blue-derived atoB gene or idi gene of mevalonic acid pathway, catalytic substrate Farnesyl pyrophosphate can be synthesized in large scale, and producing of the nerolidol can be further promoted. The terpene synthase has specificity and high efficiency, can improve the nerolidol yield, greatly overcomes the defects of a large amount of raw materials and a low nerolidol yield, reduces study cost, and ensures greenness and environmental friendliness.

The present invention relates to novel terpene synthases. The terpene synthases are capable of synthesising mono-, bi- and/or tri-cyclic sesquiterpenes having a C2-C7 or a C3-C7 bond, starting from an acyclic pyrophosphate terpene precursor, farnesyl-pyrophosphate. Accordingly, for the first time, sesquiterpene synthases catalyzing the cyclisation to the santalene and bergamotene carbon skeleton are disclosed. The present invention further relates to nucleic acid sequences encoding the sesquiterpene synthases and to methods for making terpenoids.

The invention relates to a cDNA (complementary deoxyribonucleic acid) sequence of a ganoderma lucidum terpene synthase GL22395 encoding gene and an application of the cDNA sequence. The cDNA sequence of the ganoderma lucidum terpene synthase GL22395 encoding gene is represented as Seq ID No.2, and 419 amino acids are encoded. The ganoderma lucidum terpene synthase gene GL22395 is adopted to transform escherichia coli, and endogenous FPP (farnesyl pyrophosphate) is taken as a substrate, so that terpenoid is synthesized in an internal heterogeneous source of escherichia coli.

Genes have been isolated from Pectobacterium cypripedii encoding geranylgeranyl pyrophosphate (GGPP) synthase (CrtE), phytoene synthase (CrtB), phytoene desaturase (Crtl), lycopene cyclase (CrtY), β-carotene hydroxylase (CrtZ), and zeaxanthin glucosyl transferase (CrtX) activity. The genes and their products are useful for the conversion of farnesyl pyrophosphate to carotenoids. Vectors containing those DNA segments, host cells containing the vectors and methods for producing those enzymes by recombinant DNA technology in transformed host organisms are disclosed.

The invention discloses sesquiterpene cyclase, preparation and application thereof, and a synthesis method of 2Z,4E-alpha-ionylideneehane. At first, the amino acid sequence of provided sesquiterpene cyclase BcABA3 is represented by the sequence 2, and a derived polypeptide is also provided. The sesquiterpene cyclase can catalyze farnesyl pyrophosphate cyclization to synthesize 2Z,4E-alpha-ionylideneehane. At the same time, gene sequence that encodes the amino acid sequence of sesquiterpene cyclase is provided. A recombinant protein containing the amino acid sequence is also provided. The invention further provides a method of using the sesquiterpene cyclase, the recombinant protein, and farnesyl pyrophosphate taken as the substrate to synthesize 2Z,4E-alpha-ionylideneehane and abscisic acid. The invention further provides a recombinant expression carrier containing a sesquiterpene cyclase coding gene, a converter, and applications thereof. A synthesis method of 2Z,4E-alpha-ionylideneehane is also provided; according to the synthesis method, farnesyl pyrophosphate is taken as the substrate, and the synthesis is catalyzed by sesquiterpene cyclase or recombinant sesquiterpene cyclase.

Novel proteins of microorganism E-396 (FERM BP-4283) and the DNA sequences which encode these proteins have been discovered to provide an improved biosynthetic pathway from farnesyl pyrophosphate and isopentyl pyrophosphate to various carotenoids, especially zeaxanthin, astaxanthin, adonixanthin and canthaxanthin.

The subject matter of the invention is a cosmetic and/or dermatological composition for use in the treatment of skin and/or hair disorders. More particularly, the invention relates to a cosmetic and/or dermatological composition comprising an inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, an inhibitor of farnesyl pyrophosphate synthase, or an inhibitor of one of the physiologically acceptable salts thereof and a cosmetic and/or dermatological product. The present invention finds, for example, a very advantageous use in the treatment of the effects of early ageing, in particular in terms of the skin and the hair system.

The invention relates to a saffron, a saffron endophytic fungi GGPPS (geranylgeranyl pyrophosphate synthase) gene, a gene cloning method and application, and belongs to the technical field of gene engineering. The invention discloses two genes including the saffron and GGPPS in metabolic pathway of the saffron endophytic fungi; the two genes have nucleotide sequences shown as SEQ ID NO.4 and SEQ ID NO.3, have the identical open reading frames shown as SEQ ID NO.1 and code amino acid sequences shown as code SEQ ID NO.2. The color genetic complementary reaction verifies that the GGPPS gene coding protein has a typical GGPPS enzyme function; FPP (farnesyl pyrophosphate) and IPP (isopentenyl pyrophosphate) can be catalyzed to be synthesized into the GGPPS (C<20>).

The invention provides a screening method of a farnesyl pyrophosphate synthase (FPPS) inhibitor. The screening method comprises the following steps: (1) constructing an FPPS template; (2) preparing a data set; 3) performing virtual screening based on molecular docking; 4) performing virtual screening based on the pharmacophore model; 5) calculating binding energy; 6) integrating the docking scores in the steps 3), 4) and 5), the pharmacophore model FitValue value and the binding energy to obtain the FPPS inhibitor; and 7) carrying out FPPS enzyme activity inhibition experiment on the FPPS inhibitor obtained by virtual screening, and determining the FPPS inhibitor with the structure shown in the formula I. The method gives full play to the advantages of theoretical screening, reduces the blindness of drug synthesis, effectively improves the hit rate of positive drugs, saves manpower, material resources and financial resources, and realizes the new use value of old drugs. The invention further provides application of the FPPS inhibitor obtained through screening in preparation of drugs for treating colon cancer.

The invention relates to a novel imidazole diphosphonie acid compound and a pharmaceutically-acceptable salt thereof. The diphosphonie acid compound disclosed by the invention, farnesylpyrophosphate synthetase is treated, and lipotropy is enhanced. The type of compound can be used for treating diseases including osteoporosis, hypercalcinemia and the like, and can be applied to cancer chemotherapy, immunotherapy and the like.